Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.
van Meerten T, Rozemuller H, Hol S, Moerer P, Zwart M, Hagenbeek A, Mackus WJ, Parren PW, van de Winkel JG, Ebeling SB, Martens AC. van Meerten T, et al. Among authors: van de winkel jg. Haematologica. 2010 Dec;95(12):2063-71. doi: 10.3324/haematol.2010.025783. Epub 2010 Sep 17. Haematologica. 2010. PMID: 20851867 Free PMC article.
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.
Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH. Boross P, et al. Among authors: van der poel ce, de haij s, van de winkel jg. Haematologica. 2011 Dec;96(12):1822-30. doi: 10.3324/haematol.2011.047159. Epub 2011 Aug 31. Haematologica. 2011. PMID: 21880632 Free PMC article.
Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, Parren PW, Bleeker WK. Overdijk MB, et al. Among authors: van den brakel jh, van de winkel jg. J Immunol. 2011 Sep 15;187(6):3383-90. doi: 10.4049/jimmunol.1003926. Epub 2011 Aug 10. J Immunol. 2011. PMID: 21832160 Free article.
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.
Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, Valerius T, van de Winkel JG, Glennie MJ. Teeling JL, et al. Among authors: van den brakel j, van de winkel jg. Blood. 2004 Sep 15;104(6):1793-800. doi: 10.1182/blood-2004-01-0039. Epub 2004 Jun 1. Blood. 2004. PMID: 15172969 Free article.
Novel human antibody therapeutics: the age of the Umabs.
Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Ruuls SR, et al. Among authors: van de winkel jg. Biotechnol J. 2008 Oct;3(9-10):1157-71. doi: 10.1002/biot.200800110. Biotechnol J. 2008. PMID: 18702090 Free PMC article. Review.
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. de Weers M, et al. Among authors: van der veer ms, van de winkel jg. J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27. J Immunol. 2011. PMID: 21187443 Clinical Trial.
300 results